Roivant Sciences logo

Roivant Sciences

ROIV | NASDAQ
Chart Builder DCF Calculator
$38.61
-$0.92 (-2.33%)
At close: Nov 16, 2026, 4:00 PM ET
$39.11
+$0.50 (+1.30%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.33%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
44.9
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #393/1021 (Top 38%)

Key Statistics

Market Data

Market Cap $27.98B
1D Range
38.46 40.17
52W Range
20.10 41.85

Valuation (TTM)

PE -71.50
PB 6.96
EV/EBITDA -81.03

Valuation (NTM)

Forward PE N/A
Forward PEG -32.39
Price Target $49.00
Loading financial charts...

Profile

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spec...

Sector Healthcare
Industry Biotechnology
Employees 721
IPO Date Dec 8, 2020
Website roivant.com
Fiscal Year April - March

Latest News

Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum

5 days ago · seekingalpha.com

Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology

6 days ago · globenewswire.com

Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript

7 days ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences Q2 Earnings Call Highlights

8 days ago · marketbeat.com

Roivant Sciences Q2 Earnings Call Highlights
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates

8 days ago · zacks.com

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

26 days ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results

27 days ago · marketbeat.com

Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

27 days ago · globenewswire.com

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

2 months ago · marketbeat.com

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

2 months ago · globenewswire.com

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Earnings

Latest Earnings
Nov 9, 2026
EPS
-$0.27
Beat +26.36%
REV
$35.12M
Beat +709.96%
Next Earnings
Feb 5, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$49.00
Upside
+26.91%
Buy (8)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.